QR-koda

Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study

Abstract Introduction Data suggest that women and men differ in how they experience biological treatment. This post hoc analysis of the YU-MATTER study evaluated sex-related differences in patient satisfaction and perception when switching from adalimumab (reference or biosimilar) to CT-P17 (Yuflyma...

Olles dieđut

Furkejuvvon:
Váldodahkkit: Laure Gossec, Guillaume Bouguen, Azeddine Dellal, Lucile Foulley, Caroline Habauzit, Salim Benkhalifa, Hubert Marotte
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: Adis, Springer Healthcare 2026-03-01
Ráidu:Rheumatology and Therapy
Fáttát:
Adalimumab
Adverse events
Biosimilar
CT-P17
Injection site reactions
Patient-reported outcomes
Liŋkkat:https://doi.org/10.1007/s40744-026-00840-7
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid